Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Cue Biopharma Inc.

Traders will find the top stock market stories for Friday in our daily wrap-up.


Morning News Wrap-Up, 5/1/26: Today’s Biggest Stock Market Stories!

The latest update is out from Cue Biopharma ( ($CUE) ). On April 30, 2026, Cue Biopharma entered a global (ex‑Greater China) exclusive license with...

Cue Biopharma licenses Ascendant-221 and raises new capital

Cue Biopharma stock was up after the company announced a $30 million private placement.


Why Is Cue Biopharma Stock Up Today?

The latest announcement is out from Cue Energy Resources Limited ( ($AU:CUE) ). Cue Energy Resources Limited has applied for quotation of an additi...

Cue Energy Seeks Quotation for Additional Ordinary Shares on ASX

An update from Cue Energy Resources Limited ( ($AU:CUE) ) is now available. Cue Energy Resources has issued 1,358,250 fully paid ordinary shares fo...

Cue Energy Issues New Shares on Exercise of Options, Confirms Regulatory Compliance

Cue Energy Resources Limited ( ($AU:CUE) ) just unveiled an announcement. Cue Energy has highlighted its role as a regional upstream oil and gas pr...

Cue Energy locks in long-term NT gas deal as cash returns and takeover bid shape outlook

An announcement from Cue Biopharma ( ($CUE) ) is now available. Cue Biopharma, Inc., a Nasdaq-listed immunotherapy-focused biotechnology company, m...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CUE	$23.01	-9.16%	180.06K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CUE	$23.01	-9.2%	180.06K
3
4
5
6

CUE

CUE

Get Cue Biopharma Inc. Data in Excel

Get Cue Biopharma Inc. Data in Excel